On the one hand, differentially expressed genes and enriched signaling pathways were analyzed in two groups of breast cancer patients divided according to MIR3613 CNVs from TCGA dataset (group of MIR3613 CNV ≥ 0, n = 586; group of MIR3613 CNV < 0, n = 492). This evidence concerns the gene MIR3613 and breast carcinoma.